Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743078 · ClinicalTrials.gov registry record · Phase 2
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
A Phase 2 study, sponsored by RTOG Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02743078 is a Phase 2 study that was terminated before completion, run by RTOG Foundation. The registered enrollment target is 3 participants.
The verdict
NCT02743078, a Phase 2 study, was terminated before completion, sponsored by RTOG Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
Interventions
- DRUG Bevacizumab
- DEVICE TTFields Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743078
The ClinicalTrials.gov registry entry for NCT02743078 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTOG Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02743078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743078 about?
NCT02743078 is a clinical study titled "Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma". This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
What is the current status of trial NCT02743078?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-05-09. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT02743078?
The interventions under investigation include: Bevacizumab (DRUG), TTFields Therapy (DEVICE).
Who is sponsoring clinical trial NCT02743078?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.